I find that amazing that we would have to do a phase 2 for CKD even if we have positive results on the subgroup data of BETonMACE for CKD.
If we have the funds why would they not allow us to do a phase 3 right away, especially considering the safety profile of Apabetalone. The same for the subgroup of C,... if good results why not phase 3 for next trial...?
Thanks